Cytokinetics Historical Cash Flow
| CYTK Stock | USD 43.63 0.92 2.07% |
Analysis of Cytokinetics cash flow over time is an excellent tool to project Cytokinetics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Inventory of 1.8 M or Change In Working Capital of 37.4 M as it is a great indicator of Cytokinetics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Cytokinetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cytokinetics is a good buy for the upcoming year.
Cytokinetics |
About Cytokinetics Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Cytokinetics balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cytokinetics's non-liquid assets can be easily converted into cash.
Cytokinetics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Cytokinetics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cytokinetics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Cytokinetics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.At this time, Cytokinetics' Depreciation is quite stable compared to the past year. Other Non Cash Items is expected to rise to about 53.1 M this year, although the value of Total Cashflows From Investing Activities is projected to rise to (224.1 M).
Cytokinetics cash flow statement Correlations
Click cells to compare fundamentals
Cytokinetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cytokinetics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | (2.3M) | (4.4M) | 17.5M | (10.5M) | 53.0M | 55.7M | |
| Change In Cash | 46.6M | 29.7M | (45.5M) | 46.2M | (18.2M) | (17.3M) | |
| Free Cash Flow | (2.1M) | (191.4M) | (310.9M) | (415.7M) | (399.8M) | (379.8M) | |
| Change In Working Capital | 89.1M | 8.5M | (24.7M) | 3.1M | 35.7M | 37.4M | |
| Begin Period Cash Flow | 36.4M | 83.0M | 112.7M | 67.2M | 113.4M | 119.1M | |
| Total Cashflows From Investing Activities | (74.7M) | (196.5M) | (147.8M) | (262.1M) | (235.9M) | (224.1M) | |
| Other Cashflows From Financing Activities | 9.0M | 7.9M | 181.5M | 57.9M | 233.4M | 245.1M | |
| Depreciation | 1.8M | 2.3M | 5.8M | 11.9M | 9.5M | 10.0M | |
| Other Non Cash Items | 28.2M | 32.4M | 60.5M | 24.9M | 50.6M | 53.1M | |
| Capital Expenditures | 11.1M | 48.9M | 11.3M | 1.4M | 3.9M | 5.2M | |
| Total Cash From Operating Activities | 8.9M | (142.5M) | (299.5M) | (414.3M) | (395.9M) | (376.1M) | |
| Change To Account Receivables | 743K | (47.4M) | 56.7M | (1.1M) | (15.4M) | (14.6M) | |
| Net Income | (127.3M) | (215.3M) | (389.0M) | (526.2M) | (589.5M) | (560.0M) | |
| Total Cash From Financing Activities | 234.1M | 320.0M | 516.2M | 221.3M | 930.6M | 977.1M | |
| End Period Cash Flow | 83.0M | 112.7M | 67.2M | 113.4M | 95.2M | 56.3M | |
| Change To Liabilities | 2.2M | 94.0M | 19.8M | (75.7M) | (87.0M) | (82.7M) | |
| Other Cashflows From Investing Activities | (72.1M) | (185.5M) | (98.9M) | (250.8M) | (225.7M) | (214.4M) | |
| Stock Based Compensation | 17.6M | 26.8M | 47.9M | 72.1M | 97.8M | 102.7M | |
| Investments | (185.5M) | (98.9M) | (250.8M) | 349.9M | (553.1M) | (525.4M) | |
| Change Receivables | (2.9M) | 743K | (47.4M) | 56.7M | 65.2M | 68.4M | |
| Net Borrowings | 9.9M | 1.7M | 334.7M | 473.5M | 544.6M | 571.8M | |
| Cash And Cash Equivalents Changes | (5.8M) | 46.6M | 29.7M | (45.5M) | (40.9M) | (38.9M) | |
| Cash Flows Other Operating | 18.5M | 16.0M | 64.2M | 24.0M | 27.7M | 29.0M | |
| Change To Netincome | 11.7M | 23.7M | 34.0M | 78.6M | 90.4M | 94.9M | |
| Change To Operating Activities | (6.4M) | 1.5M | 54.8M | 1.1M | 1.3M | 1.2M | |
| Issuance Of Capital Stock | 225.1M | 312.0M | 15.1M | 1.3M | 706.8M | 742.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.26) | Revenue Per Share | Quarterly Revenue Growth 9.124 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.